.jpg)
Sanofi and Regeneron's high-flying Dupixent on course for an 'inflection year' in COPD
Sanofi is on a “record-setting pace,” as it relates to Medicare and commercial coverage for Dupixent in COPD, the company said. The indication is key as Sanofi and U.S. partner Regeneron expect sales of Dupixent to reach $22 billion by 2030.
Sanofi is on a “record-setting pace,” as it relates to Medicare and commercial coverage for Dupixent in COPD, the company said. The indication is key as Sanofi and U.S. partner Regeneron expect sales of Dupixent to reach $22 billion by 2030.
